1 of 1
Story summary
- Sandoz, the Swiss drugmaker, increased its revenue guidance, and its shares rose 6.4% to 69.80 euros.
- The revenue guidance upgrade is attributed to growth in Sandoz's biosimilar product range.
- Richard Saynor, CEO of Sandoz, made the announcement during trading at the Six Swiss Exchange in Zurich, Switzerland.
